MedTrace Logo

Feasibility of the LUM Imaging System for Detection of Cancer to the Brain

NCT03717142 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2025-01-15

No results posted yet for this study

Summary

The overall objective of this study is to assess the safety and efficacy of the LUM Imaging System in imaging primary and metastatic cancer in the brain. This includes selecting a dose to determine the initial efficacy of LUM015 for the molecular imaging of low-grade gliomas, glioblastomas and cancer masses that have metastasized to the brain.

Conditions

  • Low Grade Glioma of Brain
  • Glioblastoma
  • Metastasis to Brain

Interventions

COMBINATION_PRODUCT

LUM Imaging System

Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and tissue will be imaged in vivo and ex vivo with the LUM imaging device.

Sponsors & Collaborators

  • Lumicell, Inc.

    lead INDUSTRY

Principal Investigators

  • E. Antonio Chiocca, MD, PhD · Brigham and Women's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-03
Primary Completion
2023-09-13
Completion
2024-06-14
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03717142 on ClinicalTrials.gov